Company Description
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor.
The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M.
D. Anderson Cancer Center.
The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Philippe Calais |
Contact Details
Address: 6 Liberty Square, Suite 2382 Boston, Massachusetts 02109 United States | |
| Phone | 857 837 3099 |
| Website | transcodetherapeutics.com |
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1829635 |
| CUSIP Number | 89357L501 |
| ISIN Number | US89357L5012 |
| Employer ID | 81-1065054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Chief Executive Officer and Executive Chairman of the Board |
| Thomas A. Fitzgerald M.B.A. | Chief Financial Officer, President, Vice President of Administration and Director |
| Dr. Zdravka Medarova Ph.D. | Scientific Co-Founder and Chief Scientific Officer |
| Dr. Anna Moore Ph.D. | Scientific Co-Founder, Scientific Advisor and Chair of Scientific Advisory Board |
| Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 26, 2026 | 8-K/A | [Amend] Current report |
| May 22, 2026 | 8-K | Current Report |
| May 19, 2026 | EFFECT | Notice of Effectiveness |
| May 19, 2026 | EFFECT | Notice of Effectiveness |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | PRE 14A | Other preliminary proxy statements |
| May 1, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 30, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |